New Aspects for Treatment with Fosfomycin

Name: New Aspects for Treatment with Fosfomycin
Brand: Springer Nature
SKU: 9783211819869
Availability: InStock

Best Price (Coupon Required):
Buy New Aspects for Treatment with Fosfomycin for $36.00 at @ Link.springer.com when you apply the 10% OFF coupon at checkout.
Click “Get Coupon & Buy” to copy the code and unlock the deal.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $39.99 - $39.99

BEST PRICE

Single Product Purchase

$36.00

@ Link.springer.com with extra coupon

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$39.99	$39.99		10% OFF This deals requires coupon	$36.00		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9783211819869

Condition

New

Product Description

Fosfomycin is an antimicrobial substance which is available since several years. In earlier clinical studies an oral preparation with poor absorption in a low dosage resulted in inadequate therapeutic results. The presently used parenteral administration in a dosage range of up to 250 mg/kg BW however allowed us to appreciate several unique properties of this drug which make it valuable in the treatment of serious bacterial infections. Due to its small molecular weight and complete lack of protein binding a favorable penetration in tissues and deep compartments (e.g., meninges, bone, heart valves) was observed. In addition fosfomycin shows a remarkably low toxicity and even protects from the nephrotoxigenic effects of aminoglycosides and other drugs. Earlier problems in antimicrobial susceptibility testing have been solved by addition of glucose 6 phosphate into the growth medium. Fosfomycin, the first representative of a completely new class of antibiotics does not show cross-resistance with other antibiotics; therefore pathogens of nosocomial infections, particularly methicillin- und gentamicin-resistant staphylococci are mostly susceptible to this antibiotic. Clinical investigations show a favorable therapeutic outcome in severe nosocomial infections despite of previous therapeutic approaches with various other potent antibiotics. In an international symposium in Mexico City the available clinical experience with this drug was presented and indications for the use of this antibiotic were established. Prof Dr. K. H. Spitzy Contents Summary-Zusammenfassung .

Available Colors

N/A

Available Sizes

N/A